



Pyrazolo[1,5-*a*]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO)

Aaron Reynolds^a, Raphy Hanani^a, David Hibbs^b, Annelaure Damont^c, Eleonora Da Pozzo^d, Silvia Selleri^e, Frédéric Dollé^c, Claudia Martini^d, Michael Kassiou^{a,f,g,*}

^a School of Chemistry, University of Sydney, Sydney, NSW 2006, Australia

^b Faculty of Pharmacy, University of Sydney, Sydney, NSW 2006, Australia

^c CEA, I2BM, Service Hospitalier Frédéric Joliot, F-91401 Orsay, France

^d Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Via Bonanno, 6 56126 Pisa, Italy

^e Department of Pharmaceutical Sciences, University of Florence, Via U. Schiff, 650019 Polo Scientifico Sesto Fiorentino, Italy

^f Brain and Mind Research Institute, Sydney, NSW 2050, Australia

^g Discipline of Medical Radiation Sciences, University of Sydney, Sydney, NSW 2006, Australia

ARTICLE INFO

Article history:

Received 23 June 2010

Revised 29 July 2010

Accepted 30 July 2010

Available online 4 August 2010

Keywords:

Peripheral-type benzodiazepine receptor

Translocator protein

TSPO

Steroidogenesis

Pyrazolo[1,5-*a*]pyrimidine

Neurodegeneration

Neuroprotection

Microglia

ABSTRACT

Herein, we report the synthesis of four new phenyl alkyl ether derivatives (**7**, **9–11**) of the pyrazolo[1,5-*a*]pyrimidine acetamide class, all of which showed high binding affinity and selectivity for the TSPO and, in the case of the propyl, propargyl, and butyl ether derivatives, the ability to increase pregnenolone biosynthesis by 80–175% over baseline in rat C6 glioma cells. While these compounds fit our *in silico* generated pharmacophore for TSPO binding the current model does not account for the observed functional activity.

© 2010 Elsevier Ltd. All rights reserved.

The translocator protein (TSPO), formerly known as the peripheral-type benzodiazepine receptor (PBR),¹ is ubiquitously expressed in most peripheral organs, with the highest densities in steroidogenic tissues² as well as in heart, kidney, lung and testis,³ but only minimally expressed in the healthy brain.⁴ Increased levels of TSPO expression have been noted in a number of neuroinflammatory and neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease, and stroke, coinciding with the activation of microglia, the principle immune effector cells in the central nervous system (CNS).

The TSPO is a highly lipophilic 18 kDa protein comprising 169 amino acids.⁵ Primarily located on the outer mitochondrial membrane⁶ with five trans-membrane domains, the TSPO is believed to be closely associated with the voltage-dependant ion channel (VDAC) and the adenine nucleotide transporter (ANT) as part of the mitochondrial permeability transition pore (MPTP).⁷ While its

exact physiological role remains unknown, the TSPO is implicated in several biochemical processes including cell proliferation,⁸ apoptosis,⁹ steroidogenesis,^{3,10–12} porphyrin transport and heme synthesis,¹³ and immunomodulation.¹⁴ Among these, the rate-limiting translocation of cholesterol from the outer to inner mitochondrial membrane and subsequent enzymatic side chain cleavage to form pregnenolone, the precursor to all mammalian steroids, is perhaps the best documented.

The relationship between neuroinflammation/microglial activation and TSPO expression has resulted in the development of a number of structurally diverse TSPO ligands which have been described in reviews by James et al.¹⁵ and Scarf et al.¹⁶ Some of these ligands have been shown to mediate non-sedating anxiolytic-like effects in both rodent models of anxiety¹⁷ and in humans¹⁸ related to the production of neurosteroids which enhance γ -aminobutyric acid-mediated neurotransmission.¹⁹

The synthesis and biological evaluation of the arylpyrazolo[1,5-*a*]pyrimidine acetamides, a novel and selective class of high affinity ligands for the TSPO, was first reported by Selleri et al.²⁰ The authors concluded that substitution on the pyrimidine ring is important in determining selectivity for the TSPO over the central

* Corresponding author. Address: The Brain and Mind Research Institute, 100 Mallett Street, Camperdown, NSW 2050, Australia. Tel.: +61 2 9351 0799; fax: +61 2 9351 0652.

E-mail address: michael.kassiou@sydney.edu.au (M. Kassiou).

benzodiazepine receptor (CBR) and that substituents at the 4'-position of the phenyl ring had an effect on TSPO binding affinity. Some of these compounds were shown to increase pregnenolone biosynthesis in rat C6 glioma cells with similar potency to that of known TSPO ligand, PK11195.


We aimed to explore the effect on TSPO binding affinity and pregnenolone biosynthesis of various length 4'-phenyl alkyl ethers derived from the arylpyrazolo[1,5-*a*]pyrimidine acetamide **6**, which we have previously reported.²¹

The synthetic route (Scheme 1) commenced with commercially available methyl 4-methoxybenzoate (**1**) which underwent nucleophilic attack in the presence of the stabilized carbanion derived from acetonitrile to form a tetrahedral intermediate which, upon loss of methoxide, gave the 3-oxopropanenitrile **2** in modest yield (58%). C-alkylation of **2** occurred upon treatment with sodium hydroxide to form the corresponding enolate followed by addition of commercially available *N,N*-diethylchloroacetamide and sodium iodide to afford **3** (80%). Aminopyrazole **4** was obtained in 80% yield following cyclization of a hydrazone intermediate derived from **3** and hydrazine hydrate. Treatment of **4** with 2,4-pentanedione in refluxing ethanol generated the pyrazolo[1,5-*a*]pyrimidine **5** in 93% yield via a double condensation. Cleavage of the methyl ether **5** to give the corresponding phenol **6** was achieved in the presence of refluxing 48% v/v aqueous hydrobromic acid and catalytic tetra-*n*-butylphosphonium bromide (0.10 equiv) in 54% yield.


The phenol **6** was elaborated to give the desired 4'-phenyl alkyl ethers (**7–11**) by Mitsunobu alkylation or by simple O-alkylation of the corresponding in situ generated phenoxide (Scheme 2). We have previously reported the binding of compounds **5** and **8** and their labeling with the short-lived positron-emitters carbon-11 and fluorine-18, respectively, as radioligands²² for in vivo positron emission tomography (PET) imaging studies.^{21,23–30}

The TSPO binding of compounds **5**, **7–11** and PK11195 was evaluated in a membrane binding assay using [³H]PK11195 as the radioligand and mitochondrial fractions from rat kidney as the receptor source. To determine the selectivity for the TSPO, binding to the CBR was also assessed using [³H]Ro15,1788 and rat brain tissue. The results are summarized in Table 1.

All of the new compounds (**7**, **9–11**) displayed high affinity and complete selectivity for the TSPO over the CBR as well as a large range of CNS receptors and transporters (see Supplementary data). Increasing the length of the alkyl ether had little effect on TSPO binding affinity, suggesting the possible existence of a lipophilic binding pocket that can accommodate the steric bulk of an *n*-butyl group.




Scheme 1. Reagents and conditions: (a) NaOMe, MeCN, reflux, 32 h, 58%; (b) *N,N*-diethylchloroacetamide, NaI, NaOH, EtOH/H₂O (80:20), rt, 7 h, 80%; (c) NH₂NH₂·H₂O, AcOH, EtOH, reflux, 4 h, 86%; (d) 2,4-pentanedione, EtOH, reflux, 12 h, 93%; (e) 48% v/v HBr, tetra-*n*-butylphosphonium bromide (0.10 equiv), 100 °C, 7 h, 54%.



Scheme 2. Reagents and conditions: (a) DIAD (2.2 equiv), PPh₃ (2.2 equiv), NEt₃ (0 or 2.2 equiv), ROH (2.2 equiv), THF or DMF, 0 °C → RT, 72 h; (b) NaH or K₂CO₃, DMF, 0 °C, then ROTs or RBr, rt.

Table 1

Binding affinity of compounds **5**, **7–11** and PK11195 for the TSPO and CBR



Compound	R	K _i (TSPO) (nM)	K _i (CBR) (nM)
PK11195		9.3 ± 0.5	>10,000
5	CH ₃	4.7 ± 0.2	>10,000
7	CH ₂ CH ₃	5.7 ± 0.5	>10,000
8	CH ₂ CH ₂ F	7.0 ± 0.4	>10,000
9	(CH ₂) ₂ CH ₃	1.4 ± 0.2	>10,000
10	(CH ₂) ₃ CH ₃	1.1 ± 0.1	>10,000
11	CH ₂ C≡CH	4.8 ± 0.5	>10,000

Each of the newly synthesized compounds was assessed, alongside PK11195, for its ability to increase pregnenolone biosynthesis in rat C6 glioma cells using a well developed steroidogenic assay.²⁰ Each TSPO ligand was used at the same concentration (40 μM) and at the end of the incubation period (2 h) the amount of pregnenolone was quantified by radio-immunoassay (RIA). The results are shown in Figure 1 (the values are the mean of three determinations). The known 4'-phenyl (2''-fluoroethyl) ether **8** stimulated pregnenolone biosynthesis at levels 80% above baseline, displaying significantly greater potency than PK11195 whereas the known




Figure 1. Results of steroidogenesis assay. Complete details can be found in the Supplementary data.

4'-phenyl methyl ether derivative **5** and 4'-phenyl ethyl ether derivative **7** showed no effect on steroidogenesis in the same assay. Compounds **9**, **10**, and **11**, corresponding to the propyl, butyl and propargyl ethers, respectively, displayed the greatest increase in pregnenolone biosynthesis (140–175% above baseline) of any high affinity TSPO ligand within this class assessed using this assay.

In an effort to understand the structural dependence on the relative activities of the TSPO ligands **5**, **7**–**11**, it was decided to determine the likely pharmacophore hypothesis responsible for activity. A number of ligands with high binding affinity for the TSPO have been previously reported,^{15,16} and these were used in the construction of the initial hypotheses.

A collection of 44 compounds, representing a variety of classes of TSPO ligands, that are available in our laboratory were built using MAESTRO 9.0,³¹ and energy minimized using the conjugate gradient method as implemented in MacroModel,³² with a convergence criterion of 0.05 kcal A⁻¹, with the OPLS 2005 potential. Solvation effects were modeled using a continuum field, with a dielectric constant of 1.0. Each molecule then underwent a conformational analysis, retaining only those conformers with a relative energy value within 10 kcal mol⁻¹ of the minimized parent molecule.

Our best hypothesis using PHASE³³ supports the recent findings of Tuccinardi et al.³⁴ AHRRR, where A = hydrogen bond acceptor, H = hydrophobic group, and R = ring system (Fig. 2).

Given the small number of ligands available in this study it was not possible to determine the structural reasons for the observed differences in binding affinity and functional activity of the ligands involved using the common pharmacophore structure. The results of the in silico property prediction³⁵ (see Supplementary data) also

offer no common insight into the possible ligand-based mechanism of action of the compounds presented here. Using a number of the standard properties used in chemoinformatics, no noticeable trends were observed, once again, presumably due to the small number of ligands available. We are currently developing a comparative model of the human TSPO, which will provide a much clearer picture of the intermolecular interactions of this class of compounds with the protein.

In summary, we have synthesized four new pyrazolo[1,5-*a*]pyrimidine acetamides substituted with various length alkyl ethers at the 4'-position of the phenyl ring. All of these compounds displayed high affinity for the TSPO with complete selectivity over the CBR as well as a large range CNS receptors and transporters. Compounds **9**, **10**, and **11** represent the most potent modulators of steroidogenesis within this class to date and have potential therapeutic applications as anxiolytics or neuroprotective agents.

Acknowledgments

K_i determinations for targets included in the SI were generously provided by the National Institute of Mental Health's Psychoactive Drug Screening Program, Contract #NO1MH32004 (NIMH PDSP). The NIMH PDSP is Directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda MD, USA. For experimental details please refer to the PDSP web site <http://pdsp.med.unc.edu/>.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.bmcl.2010.07.135](https://doi.org/10.1016/j.bmcl.2010.07.135).

References and notes

- Papadopoulos, V.; Baraldi, M.; Guilarte, T. R.; Knudsen, T. B.; Lacapere, J.-J.; Lindemann, P.; Norenberg, M. D.; Nutt, D.; Weizman, A.; Zhang, M.-R.; Gavish, M. *Trends Pharmacol. Sci.* **2006**, 27, 402.
- Verma, A.; Snyder, S. H. *Annu. Rev. Pharmacol. Toxicol.* **1989**, 29, 307.
- Gavish, M.; Katz, Y.; Bar-Ami, S.; Weizman, R. J. *Neurochem.* **1992**, 58, 1589.
- Gavish, M.; Bachman, I.; Shoukrun, R.; Katz, Y.; Veenman, L.; Weisinger, G.; Weizman, A. *Pharmacol. Rev.* **1999**, 51, 629.
- Beurdeley-Thomas, A.; Miccoli, L.; Oudard, S.; Dutrillaux, B.; Poupon, M. F. *J. Neurooncol.* **2000**, 46, 45.
- Anholt, R. R.; Pedersen, P. L.; De Souza, E. B.; Snyder, S. H. *J. Biol. Chem.* **1986**, 261, 576.
- McEnery, M. W.; Snowman, A. M.; Trifiletti, R. R.; Snyder, S. H. *Proc. Natl. Acad. Sci. U.S.A.* **1992**, 89, 3170.
- Alho, H.; Varga, V.; Krueger, K. E. *Cell Growth Differ.* **1994**, 5, 1005.
- Chelli, B.; Lena, A.; Vanacore, R.; Pozzo, E. D.; Costa, B.; Rossi, L.; Salvetti, A.; Scatena, F.; Ceruti, S.; Abbraccio, M. P.; Gremigni, V.; Martini, C. *Biochem. Pharmacol.* **2004**, 68, 125.
- Costa, E.; Auta, J.; Guidotti, A.; Korneyev, A.; Romeo, E. *J. Steroid Biochem. Mol. Biol.* **1994**, 49, 385.
- Papadopoulos, V.; Amri, H.; Boujrad, N.; Cascio, C.; Culty, M.; Garnier, M.; Hardwick, M.; Li, H.; Vidic, B.; Brown, A. S.; Reversa, J. L.; Bernassau, J. M.; Drieu, K. *Steroids* **1997**, 62, 21.
- Krueger, K. E.; Papadopoulos, V. *Annu. Rev. Pharmacol. Toxicol.* **1992**, 32, 211.
- Taketani, S.; Kohno, H.; Furukawa, T.; Tokunaga, R. *J. Biochem. (Tokyo)* **1995**, 117, 875.
- Zavala, F. *Pharmacol. Ther.* **1997**, 75, 199.
- James, M. L.; Salleri, S.; Kassiou, M. *Curr. Med. Chem.* **2006**, 13, 1991.
- Scarf, A. M.; Ittner, L. M.; Kassiou, M. *J. Med. Chem.* **2009**, 52, 581.
- Kita, A.; Furukawa, K.; Kita, A.; Furukawa, K. *Pharmacol., Biochem. Behav.* **2008**, 89, 171.
- Rupprecht, R.; Rammes, G.; Eser, D.; Baghai Thomas, C.; Schule, C.; Nothdurfter, C.; Troxler, T.; Gentsch, C.; Kalkman Hans, O.; Chaperon, F.; Uzunov, V.; McAllister Kevin, H.; Bertaina-Anglade, V.; La Rochelle Christophe, D.; Tuerck, D.; Floesser, A.; Kiese, B.; Schumacher, M.; Landgraf, R.; Holsboer, F.; Kucher, K. *Science* **2009**, 325, 490.
- Taliani, S.; Da Settimo, F.; Da Pozzo, E.; Chelli, B.; Martini, C. *Curr. Med. Chem.* **2009**, 16, 3359.
- Selleri, S.; Bruni, F.; Costagli, C.; Costanzo, A.; Guerrini, G.; Ciciani, G.; Costa, B.; Martini, C. *Bioorg. Med. Chem.* **2001**, 9, 2661.
- James, M. L.; Fulton, R. R.; Henderson, D. J.; Eberl, S.; Meikle, S. R.; Thomson, S.; Allan, R. D.; Dollé, F.; Fulham, M. J.; Kassiou, M. *Bioorg. Med. Chem.* **2005**, 13, 6188.




Figure 2. Overlay of compounds **8**, **9**, and **10** illustrating the common pharmacophore hypothesis (AHRRR). Pink sphere—hydrogen bond acceptor, green sphere—hydrophobic group, tan hoop—ring system.

22. Dollé, F.; Luus, C.; Reynolds, A.; Kassiou, M. *Curr. Med. Chem.* **2009**, *16*, 2899.
23. Boutin, H.; Chauveau, F.; Thominaux, C.; Gregoire, M. C.; James, M. L.; Trebossen, R.; Hantraye, P.; Dollé, F.; Tavitian, B.; Kassiou, M. *J. Nucl. Med.* **2007**, *48*, 573.
24. James, M. L.; Fulton, R. R.; Vercoullie, J.; Henderson, D. J.; Garreau, L.; Chalon, S.; Dollé, F.; Costa, B.; Guilloteau, D.; Kassiou, M. *J. Nucl. Med.* **2008**, *49*, 814.
25. Chauveau, F.; Van Camp, N.; Dollé, F.; Kuhnast, B.; Hinnen, F.; Damont, A.; Boutin, H.; James, M. L.; Kassiou, M.; Tavitian, B. *J. Nucl. Med.* **2009**, *50*, 468.
26. Thominaux, C.; Dollé, F.; James, M. L.; Bramouille, Y.; Boutin, H.; Besret, L.; Gregoire, M. C.; Valette, H.; Bottlaender, M.; Tavitian, B.; Hantraye, P.; Salleri, S.; Kassiou, M.; Hantraye, P. *Appl. Radiat. Isot.* **2006**, *64*, 570.
27. Damont, A.; Hinnen, F.; Kuhnast, B.; Schöllhorn-Peyronneau, M.-A.; James, M.; Luus, C.; Tavitian, B.; Kassiou, M.; Dollé, F. *J. Labelled Compd. Radiopharm.* **2008**, *51*, 286.
28. Endres, C. J.; Pomper, M. G.; James, M.; Uzuner, O.; Hammoud, D. A.; Watkins, C. C.; Reynolds, A.; Hilton, J.; Dannals, R. F.; Kassiou, M. *J. Nucl. Med.* **2009**, *50*, 1276.
29. Doorduyn, J.; Klein, H. C.; Dierckx, R. A.; James, M.; Kassiou, M.; de Vries, E. F. J. *Mol. Imaging Biol.* **2009**, *11*, 386.
30. Martín, A.; Boisgard, R.; Thézé, B.; Van Camp, N.; Kuhnast, B.; Damont, A.; Kassiou, M.; Dollé, F.; Tavitian, B. *J. Cereb. Blood Flow Metab.* **2010**, *30*, 230.
31. MAESTRO (version 9.0), Schrodinger LLC, New York (USA), 2010.
32. MACROMODEL (version 3.0) Schrodinger LLC, New York (USA), 2010.
33. PHASE (version 3.0), Schrodinger LLC, New York (USA), 2010.
34. Tuccinardi, T.; Taliani, S.; Bellandi, M.; Da Settimo, F.; Da Pozzo, E.; Martini, C.; Martinelli, A. *ChemMedChem* **2009**, *4*, 1686.
35. QIKPROP (version 3.2) Schrodinger LLC, New York (USA), 2010.